Bacterial Infections

Inclusion Criteria

- Males or females >/=18 years old
 - Adequate venous access for a minimum of 2 I.V. doses of study drug
 -  Acute Bacterial Skin and skin structure infection (ABSSSI) meeting at least 1 of the clinical syndrome definitions listed below and requiring I.V. antibiotic therapy. Local symptoms must have started within 7 days before the Screening Visit
 --  Cellulitis/erysipelas
 --  Major cutaneous abscess
 -- Wound Infection
 - Suspected or documented gram-positive infection from baseline Gram stain or culture.

Exclusion Criteria

- Uncomplicated skin and skin structure infections such as furuncles, minor abscesses
 - Infections associated with, or in close proximity to, a prosthetic device
 - Severe sepsis or septic shock
 - Known bacteremia at time of screening
 -  ABSSSI due to or associated with any of the following: 
 -- Suspected or documented gram-negative pathogens in patients with cellulitis/erysipelas or major cutaneous abscess that require an antibiotic with specific gram-negative coverage. Patients with wound infections where gram-negative adjunctive therapy is warranted may be enrolled if they meet the other eligibility criteria
 -- Diabetic foot infections, gangrene, or perianal abscess
 -- Concomitant infection at another site not including a secondary ABSSSI lesion (eg, septic arthritis, endocarditis, osteomyelitis)
 --  Infected burns
 -- Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous)
 -- Any evolving necrotizing process (ie, necrotizing fasciitis)
 - Use of antibiotics as follows:
 -- Systemic antibiotic with gram-positive cocci activity for the treatment of any infection within 24 hours before the first infusion of study drug
 -- Patients who failed prior therapy for the primary infection site are also excluded from enrollment
 -- Topical antibiotic on the primary lesion within 24 hours before the first infusion of study drug except for antibiotic/antiseptic-coated dressing applied to the clean postsurgical wound
 - Administration of Linezolid within 30 days before the first infusion of the study drug
 - Recent history of opportunistic infections where the underlying cause of these infections is still active (eg, leukemia, transplant, acquired immunodeficiency syndrome [AIDS])
 - Previous exposure to Tedizolid Phosphate treatment